Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics develops cell and exosome-based therapeutics for rare diseases, with Deramiocel, an allogeneic cardiac-derived cell therapy, as its lead program for Duchenne muscular dystrophy. Company news commonly covers HOPE-3 clinical data, Biologics License Application communications with the FDA, regulatory designations for Deramiocel, and manufacturing activities tied to the DMD program.
Updates also include financial results, corporate presentations at neurology and muscular dystrophy medical meetings, collaboration revenue references tied to its U.S. Distribution Agreement with Nippon Shinyaku, and preclinical work using the StealthX exosome platform for vaccinology and delivery of oligonucleotides, proteins, and small-molecule therapeutics.
Capricor Therapeutics (NASDAQ: CAPR) announced that the independent Data and Safety Monitoring Board (DSMB) has approved the continuation of its Phase II clinical trial assessing CAP-1002 for severe COVID-19 treatment. The DSMB's safety review found no significant issues, allowing the trial, which includes up to 60 patients, to proceed. CAP-1002 aims to mitigate the cytokine storm, a severe inflammatory response in COVID-19 patients. Initial case data suggest promise for CAP-1002 in addressing cardiac complications associated with COVID-19, with results expected in H1 2021.
Capricor Therapeutics (NASDAQ: CAPR) announced the initiation of its Phase 2 INSPIRE trial for CAP-1002, focusing on treating severe COVID-19 patients. The first two patients have been dosed, with the study set to enroll up to 60 participants requiring supplemental oxygen. CAP-1002 utilizes allogeneic cardiosphere-derived cells to target the cytokine storm associated with COVID-19. This trial aims to assess the safety and efficacy of the treatment, particularly for patients facing high risks of morbidity or cardiac complications linked to COVID-19.
Capricor Therapeutics (NASDAQ: CAPR) announced positive preclinical data for a multivalent exosome-mRNA vaccine targeting COVID-19, demonstrating long-lasting immunity to multiple SARS-CoV-2 proteins. The company is expanding its exosome platform technology while advancing its CAP-1002 program for Duchenne Muscular Dystrophy. In Q3 2020, Capricor reported a net loss of approximately $3.9 million, with cash and marketable securities totaling $35.3 million. The company aims to initiate patient enrollment in upcoming clinical studies and explore partnerships to enhance its pipeline.
Capricor Therapeutics (NASDAQ: CAPR) announced positive preclinical results for its novel exosome-based mRNA vaccine for COVID-19, developed in collaboration with Johns Hopkins University. The vaccine shows potential in inducing long-lasting immunity to multiple SARS-CoV-2 proteins. Key findings include a safe exosome formulation that delivers functional mRNA and generates persistent cellular immune responses. Capricor plans to schedule a pre-IND meeting with the FDA to discuss clinical development strategies. The company reported a net loss of approximately $3.9 million for Q3 2020 with $35.3 million in cash on hand.
Capricor Therapeutics (NASDAQ: CAPR) will announce its third-quarter financial results for 2020 after market close on November 12, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update.
Capricor focuses on developing cell and exosome-based therapeutics, with its lead candidate, CAP-1002, targeting Duchenne muscular dystrophy and COVID-19 cytokine storms. The company is also exploring exosome vaccines for COVID-19.
On September 23, 2020, Capricor Therapeutics (NASDAQ: CAPR) announced that it will present data from the Phase II HOPE-2 clinical trial for its lead product CAP-1002, targeting Duchenne muscular dystrophy (DMD), at the World Muscle Society Virtual Congress on October 1. The trial showed significant improvements in upper limb, cardiac, and respiratory functions after 12 months of treatment, with p-values less than 0.05. CEO Dr. Linda Marbán emphasized the importance of this therapy for DMD patients, as treatment options remain limited and a pathway for potential FDA approval is under discussion.
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, announced that CEO Linda Marbán, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:30 AM ET. Capricor specializes in first-in-class cell and exosome-based therapeutics aimed at treating diseases such as Duchenne muscular dystrophy and COVID-19. The presentation will be accessible via webcast, providing insights into the company's innovative approaches and ongoing clinical developments.
Capricor Therapeutics (NASDAQ:CAPR) announced its presentation at the LD 500 investor conference on September 4, 2020, at 9:20 AM ET. CEO Linda Marbán will present to a virtual audience, reflecting on the challenges of COVID-19 in hosting physical events. The LD 500, taking place from September 1-4, is designed to be accessible to everyone, showcasing unique companies in the microcap market. Capricor focuses on cell and exosome-based therapeutics, with lead candidate CAP-1002 in development for Duchenne muscular dystrophy and COVID-19.
Capricor Therapeutics (NASDAQ: CAPR) announced FDA acceptance of its IND application for a Phase 2 clinical trial of CAP-1002 targeting COVID-19. The INSPIRE Trial will enroll 60 patients requiring supplemental oxygen across diverse U.S. sites. The trial aims to evaluate the safety and efficacy of CAP-1002, which has shown promise in managing cardiac complications from COVID-19. Capricor focuses on innovative cell and exosome-based therapies for various diseases, with CAP-1002 also under investigation for Duchenne muscular dystrophy.
Capricor Therapeutics (NASDAQ: CAPR) reported positive progress in its COVID-19 and Duchenne Muscular Dystrophy (DMD) programs. The company is advancing an exosome-based mRNA vaccine capable of generating antibody responses against COVID-19, currently in animal studies. A Phase II IND for CAP-1002 targeting severe COVID-19 patients has been submitted to the FDA. Financially, Capricor experienced a net loss of $3.5 million for Q2 2020, but increased cash reserves to $36.3 million following a $29.4 million capital raise. The company plans to host a conference call to discuss these developments.